Obesity Drugs Gain Momentum in India as Market Grows Over Fourfold

The anti-obesity drug market in India experienced a remarkable fourfold increase from March 2021 to March 2025 according to PharmaTrac data with a value growth from Rs 133 crore to Rs 576 crore. The market points to lifestyle disorders as well as consumer demand for proven weight-loss medications as the main reasons for its explosive growth.

Rybelsus from Novo Nordisk dominates the Indian anti-obesity drug market through its semaglutide-based pill version that grew from Rs 11 crore to Rs 397 crore since March 2022 with a market share of 69%. Eli Lilly’s Mounjaro (tirzepatide) was released as a once-weekly injectable product that provides weight management solutions together with type 2 diabetes treatment leading to higher market acceptance. The drug offers affordable pricing of Rs 3,500 per dose and attracts customers fast becoming popular in the market.

“Rybelsus had propelled the growth of this market. Mounjaro is expected to supplement and accelerate this growth,” said Sheetal Sapale, VP, Commercial, PharmaTrac.

Novo Nordisk plans to bring Wegovy, its semaglutide injection with cardiovascular advantages to the Indian market in the near future.

A growing number of overweight adults along with diabetes and hypertension cases in India leads to escalating demand for weight-loss medications particularly semaglutide and tirzepatide which propelled this sector into India’s fastest-growing pharmaceutical segment.